Thymosin α-1
28-amino-acid thymic peptide immunomodulator (synthetic form of endogenous thymosin alpha-1)
- Class
- Immune modulator
- Half-life
- ~2 hours
- Route
- Subcutaneous (SubQ)
- Cadence
- Multiple per week
- Evidence
- Human clinical trials
Overview
Thymosin α-1 is an immune-calibrating peptide with one of the deepest clinical records in the peptide world. It's approved in 35+ countries under the brand name Zadaxin for chronic hepatitis B and C — though not in the US. Twice-weekly subcutaneous injection (1.6 mg is the standard clinical dose). Unlike immune stimulants that just crank everything up, thymosin α-1 is a genuine modulator: it helps underactive immune responses mount a better defense while supporting regulatory pathways that keep overactive immunity in check.
The mechanism centers on Toll-like receptors — specifically TLR2 and TLR9 — on dendritic cells, the immune system's 'training instructors.' When thymosin α-1 binds these receptors, it drives dendritic cell maturation and shifts the immune response toward a Th1 pattern (the kind that fights viruses and intracellular pathogens). It also boosts regulatory T-cell and IDO pathways that prevent runaway inflammation. This bidirectional calibration is what sets it apart from drugs that just push the accelerator.
The agency's 2023 restriction on compounding access cited theoretical immunogenicity concerns — a plausible consideration for any subcutaneous peptide — though published trials extending 12+ months show no evidence of antibody-related adverse events or loss of efficacy.
Safety considerations
A few of the safety signals worth knowing — the full list, with dosing context and what to monitor, is inside AIx Core.
- Not approved by the FDA, EMA, or MHRA. Sold in research/compounding markets; purity and peptide content vary widely between sources.
- Exceptionally clean safety record across 30+ trials and 11,000+ subjects. Most common adverse events: injection-site reactions (5–8%), transient fatigue (<3%). No major organ toxicity, no signal for autoimmune disease induction.
- Only one serious adverse event in the FDA FAERS database — a trial participant on concurrent peginterferon alfa-2a who developed anxiety, atrial fibrillation, and transient TSH suppression. Both drugs were on board; attribution unclear.
+ 4 more safety notes inside AIx Core →
Commonly monitored
Markers and signals people track when researching Thymosin α-1.
- CD4/CD8 ratio (if you have access to immunophenotyping — some clinics monitor this during thymosin α-1 therapy)
- Viral load (if using for hepatitis B/C or chronic viral infection)
- Subjective immune resilience (frequency of infections, recovery speed)
- Injection-site reactions (mild redness/discomfort is common but should resolve in <30 min)
- Fatigue or flu-like symptoms in the first few doses (usually transient)
Frequently asked questions
What is Thymosin α-1?
28-amino-acid thymic peptide immunomodulator (synthetic form of endogenous thymosin alpha-1). Thymosin α-1 is an immune-calibrating peptide with one of the deepest clinical records in the peptide world. It's approved in 35+ countries under the brand name Zadaxin for chronic hepatitis B and C — though not in the US. Twice-weekly subcutaneous injection (1.6 mg is the standard clinical dose). Unlike immune stimulants that just crank everything up, thymosin α-1 is a genuine modulator: it helps underactive immune responses mount a better defense while supporting regulatory pathways that keep overactive immunity in check.
How is Thymosin α-1 administered?
Subcutaneous (SubQ), typically multiple per week.
What is the half-life of Thymosin α-1?
~2 hours — Short serum half-life but durable immunologic effects persist days after dosing.
Is Thymosin α-1 approved for human use?
Thymosin α-1 is investigational — not approved by the FDA, EMA, or MHRA for human use at the time of writing.
What does the evidence show for Thymosin α-1?
Evidence tier: Human clinical trials. Zhang et al. 2009 meta-analysis (8 trials, 583 patients, hepatitis B): combination lamivudine + thymosin α-1 significantly improved ALT normalization, virological response, and HBeAg seroconversion vs lamivudine alone — relative risk for seroconversion was 2.31 (95% CI 1.52–3.51).
What is commonly monitored when researching Thymosin α-1?
Commonly tracked markers + signals: CD4/CD8 ratio (if you have access to immunophenotyping — some clinics monitor this during thymosin α-1 therapy), Viral load (if using for hepatitis B/C or chronic viral infection), Subjective immune resilience (frequency of infections, recovery speed), Injection-site reactions (mild redness/discomfort is common but should resolve in <30 min), Fatigue or flu-like symptoms in the first few doses (usually transient).
Related compounds
Open this in AIx Core for the full picture
Mechanism breakdown, receptor pathway diagram, full safety list, monitored items, source citations, and one-tap add-to-protocol. Free with any account.